Challenges of Non-alcoholic Fatty Liver (NAFLD) Management: Literature Review

Maged Naser, Mohamed M. Nasr, Lamia H. Shehata

Abstract


Non-alcoholic fatty liver (NAFLD) is a common global disease, and its burden is predicted to increase because of the developing epidemic of obesity and diabetes. The key undertaking among NAFLD patients is to identify people with advanced fibrosis (F3,F4), who are at excessive threat of growing complications and will gain from specialized management and treatment with new pharmacotherapies whilst they may be approved. Liver biopsy seems unrealistic and unsuitable in practice, given the large number of excessive-risk patients and its well-known limitations. Non-invasive sequential algorithms using fibrosis-4 index as first-line test , accompanied with the aid of vibration-managed transient elastography or patented blood test, are the fine method for case finding of high-risk subjects. In truth, they may be now encouraged by way of numerous worldwide guidelines, and ought to be used and disseminated to increase awareness among physicians liver clinics wherein most NAFLD patients are seen.


Keywords


Non-Alcoholic Fatty Liver Disease; Elastography; Vibration Controlled Transient Elastography; Fibroscan; Liver Fibrosis.

Full Text:

PDF

References


- Angulo, Paul, et al. "Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease." Gastroenterology 145.4 (2013): 782-789.‏

- Hagström, Hannes, et al. "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD." Journal of hepatology 67.6 (2017): 1265-1273.‏

- Ekstedt, Mattias, et al. "Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up." Hepatology 61.5 (2015): 1547-1554.‏

- Younossi, Zobair M., et al. "Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality." Hepatology 53.6 (2011): 1874-1882.‏

- Taylor, Rod S., et al. "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis." Gastroenterology 158.6 (2020): 1611-1625.‏

- Dulai, Parambir S., et al. "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis." Hepatology 65.5 (2017): 1557-1565.‏

- Sanyal, Arun J., et al. "Prospective study of outcomes in adults with nonalcoholic fatty liver disease." New England Journal of Medicine 385.17 (2021): 1559-1569.‏

- Younossi, Zobair M., et al. "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial." The Lancet 394.10215 (2019): 2184-2196.‏

- Sanyal, A. J., S. L. Friedman, and A. J. McCullough. "Dimick-Santos LAmerican Association for the Study of Liver Diseases United States Food and Drug Administration Food and Drug Administration Joint Workshop." Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-US Hepatology 61.04 (2015): 1392-1405.‏

- Alkayyali, Tasnim, et al. "Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease." Acta diabetologica 57 (2020): 613-618.‏

- Boursier, Jérôme, et al. "Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications." Clinical Gastroenterology and Hepatology 21.5 (2023): 1243-1251.‏

- Patel, PreyaJanubhai, et al. "A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at‐risk populations in primary care." Hepatology communications 2.8 (2018): 897-909.‏

- McPherson, Stuart, et al. "Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis." Official journal of the American College of Gastroenterology| ACG 112.5 (2017): 740-751.‏

- Qadri, Sami, et al. "Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease." The Journal of Clinical Endocrinology & Metabolism 107.5 (2022): e2008-e2020.‏

- Unalp‐Arida, Aynur, and Constance E. Ruhl. "Noninvasive fatty liver markers predict liver disease mortality in the US population." Hepatology 63.4 (2016): 1170-1183.‏

- Hagström, Hannes, et al. "Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease." Journal of hepatology 73.5 (2020): 1023-1029.‏

- Castera, Laurent, Mireen Friedrich-Rust, and Rohit Loomba. "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease." Gastroenterology 156.5 (2019): 1264-1281.‏

- Vali, Yasaman, et al. "FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis." Journal of clinical medicine 10.11 (2021): 2415.‏

- Vali, Yasaman, et al. "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis." Journal of hepatology 73.2 (2020): 252-262.

- Van Dijk, Anne-Marieke, et al. "Systematic review with meta-analyses: diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease." Journal of clinical medicine 10.13 (2021): 2910.‏

-‏ Guillaume, Maeva, et al. "Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres." Alimentary pharmacology & therapeutics 50.11-12 (2019): 1214-1222.‏

- Boursier, Jérôme, et al. "New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD." Journal of hepatology 71.2 (2019): 389-396.‏

- Castera, Laurent, and Jérôme Boursier. "Noninvasive algorithms for the case finding of “at-risk” patients with NAFLD." Seminars in Liver Disease. Vol. 42. No. 03. Thieme Medical Publishers, Inc., 2022.‏

- Friedrich-Rust, Mireen, Thierry Poynard, and Laurent Castera. "Critical comparison of elastography methods to assess chronic liver disease." Nature reviews Gastroenterology & hepatology 13.7 (2016): 402-411.‏

- Eddowes, Peter J., et al. "Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease." Gastroenterology 156.6 (2019): 1717-1730.‏

- Siddiqui, Mohammad S., et al. "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease." Clinical Gastroenterology and Hepatology 17.1 (2019): 156-163.‏

- Mózes, Ferenc Emil, et al. "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis." Gut 71.5 (2022): 1006-1019.‏

- Selvaraj, Emmanuel Anandraj, et al. "Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis." Journal of hepatology 75.4 (2021): 770-785.‏

- Panel, Clinical Practice Guideline, et al. "EASL Clinical Practice Guidelines on non-invasive tests for evaluation

- Tsochatzis, Emmanuel A., and Philip N. Newsome. "Non-alcoholic fatty liver disease and the interface between primary and secondary care." The lancet Gastroenterology & hepatology 3.7 (2018): 509-517.‏

- Majumdar, Avik, et al. "Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study." Hepatology 71.2 (2020): 627-642.‏

- Canivet, Clémence M., et al. "Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD." Hepatology 77.3 (2023): 920-930.‏

- Boursier, Jerome, et al. "Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events." Journal of Hepatology 76.5 (2022): 1013-1020.‏

- Mansour, Dina, et al. "Embedding assessment of liver fibrosis into routine diabetic review in primary care." JHEP Reports 3.4 (2021): 100293.‏

- Glyn‐Owen, Kate, et al. "The combined effect of alcohol and body mass index on risk of chronic liver disease: a systematic review and meta‐analysis of cohort studies." Liver International 41.6 (2021): 1216-1226.‏

- Harman, David J., et al. "Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross‐sectional study using transient elastography." Alimentary pharmacology & therapeutics 47.4 (2018): 504-515.‏

- Innes, Hamish, et al. "Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity." Hepatology 75.2 (2022): 369-378.‏

- Kanwal, Fasiha, et al. "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease." Gastroenterology 161.5 (2021): 1657-1669.‏

- Cusi, Kenneth, et al. "American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)." Endocrine Practice 28.5 (2022): 528-562.‏

- Kanwal, Fasiha, et al. "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease." Gastroenterology 161.5 (2021): 1657-1669.‏

- Jung, Jinho, et al. "MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis." Gut 70.10 (2021): 1946-1953.‏

- Noureddin, Mazen, et al. "MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis." Journal of hepatology 76.4 (2022): 781-787.‏

- Kim, Beom Kyung, et al. "Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD." Journal of hepatology 77.6 (2022): 1482-1490.‏

- Noureddin, Mazen, Stephen A. Harrison, and Naim Alkhouri. "MEFIB vs. MAST and FAST: Not a competition but useful tools." Journal of Hepatology 80.1 (2024): e35-e36.‏

- Castera, Laurent, Mireen Friedrich-Rust, and Rohit Loomba. "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease." Gastroenterology 156.5 (2019): 1264-1281.‏

- Sberna, A. L., et al. "European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes." Diabetic Medicine 35.3 (2018): 368-375.‏

- Mátis, Dóra, et al. "Improved body composition decreases the fat content in non-alcoholic fatty liver disease, a meta-analysis and systematic review of longitudinal studies." Frontiers in Medicine 10 (2023): 1114836.‏

- Rinella, Mary E., et al. "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease." Hepatology 77.5 (2023): 1797-1835.‏

- Barrón-Cabrera, Elisa, et al. "Physical activity protocols in non-alcoholic fatty liver disease management: A systematic review of randomized clinical trials and animal models." Healthcare. Vol. 11. No. 14. MDPI, 2023.‏

- Wang, Shu-ting, et al. "Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials." BMC gastroenterology 20 (2020): 1-12.‏

- Xiong, Yingzhe, et al. "Effect of different exercise methods on non-alcoholic fatty liver disease: a meta-analysis and meta-regression." International Journal of Environmental Research and Public Health 18.6 (2021): 3242.‏

- Bischoff, Stephan C., et al. "European guideline on obesity care in patients with gastrointestinal and liver diseases–Joint ESPEN/UEG guideline." Clinical Nutrition 41.10 (2022): 2364-2405.‏

- Gofton, Cameron, et al. "MAFLD: How is it different from NAFLD?." Clinical and molecular hepatology 29.Suppl (2023): S17.‏

- Hazlehurst, Jonathan M., and Jeremy W. Tomlinson. "Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders." European Journal of Endocrinology 169.2 (2013): R27-R37.‏

- Ranjbar, Golnaz, Dimitri P. Mikhailidis, and Amirhossein Sahebkar. "Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!." Metabolism 101 (2019): 154001.‏

- Rieg, Timo, and Volker Vallon. "Development of SGLT1 and SGLT2 inhibitors." Diabetologia 61.10 (2018): 2079-2086.‏

- Jasleen, Bains, et al. "Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors: benefits versus risk." Cureus 15.1 (2023).‏

- van der Aart-van der Beek, Annemarie B., Rudolf A. de Boer, and Hiddo JL Heerspink. "Kidney and heart failure outcomes associated with SGLT2 inhibitor use." Nature Reviews Nephrology 18.5 (2022): 294-306.‏

- Nasiri-Ansari, Narjes, et al. "Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE (-/-) mice by activating autophagy and reducing ER stress and apoptosis." International journal of molecular sciences 22.2 (2021): 818.‏

- Shaaban, Hager H., et al. "Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms." Life Sciences 308 (2022): 120956.‏

- Shaaban, Hager H., et al. "Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms." Life Sciences 308 (2022): 120956.‏

- Sun, Lei, et al. "Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials." Clinics and Research in Hepatology and Gastroenterology 46.4 (2022): 101876.‏

- Bellanti, Francesco, et al. "Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease." World journal of gastroenterology 28.26 (2022): 3243.‏

- Kuchay, Mohammad Shafi, et al. "Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)." Diabetes care 41.8 (2018): 1801-1808.‏

- Zhang, Yuyuan, et al. "Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis." Frontiers in Endocrinology 13 (2022): 836455.‏

- Gu, Yunpeng, et al. "Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials." Frontiers in Pharmacology 14 (2023): 1102792.‏

- Phrueksotsai, Susrichit, et al. "The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease." Journal of gastroenterology and hepatology 36.10 (2021): 2952-2959.‏

- Arai, Taeang, et al. "Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus." Hepatology communications 6.11 (2022): 3073-3082.‏

- Bułdak, Łukasz, et al. "Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1 E7) in a protein kinase A-dependent manner." Journal of Applied Biomedicine 20.4 (2022).‏

- Bułdak, Łukasz, et al. "Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1 E7 cell line subjected to hyperglycemia and oxidative stress." Postępy Higieny i Medycyny Doświadczalnej 76.1 (2022): 16-23.‏

- Bułdak, Łukasz, et al. "The impact of exenatide (a GLP 1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions." Experimental and therapeutic medicine 17.4 (2019): 2861-2869.‏

- Armstrong, Matthew James, et al. "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study." The Lancet 387.10019 (2016): 679-690.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Kamata, Shotaro, Akihiro Honda, and Isao Ishii. "Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease." Biomolecules 13.8 (2023): 1264.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Pratt, Edward, et al. "Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: a Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes." Diabetes, Obesity and Metabolism 25.9 (2023): 2642-2649.‏

- Cusi, Kenneth, et al. "American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)." Endocrine Practice 28.5 (2022): 528-562.‏

- El, Kimberley, et al. "The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets." Nature Metabolism 5.6 (2023): 945-954.‏

- Thomas, Melissa K., et al. "Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes." The Journal of Clinical Endocrinology & Metabolism 106.2 (2021): 388-396.‏

-Thomas, Melissa K., et al. "Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes." The Journal of Clinical Endocrinology & Metabolism 106.2 (2021): 388-396.‏

- Hartman, Mark L., et al. "Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes." Diabetes Care 43.6 (2020): 1352-1355.‏

- Gastaldelli, Amalia, et al. "Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial." The lancet Diabetes & endocrinology 10.6 (2022): 393-406.‏

- Romero-Gómez, Manuel, et al. "A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease." Journal of Hepatology 79.4 (2023): 888-897.‏

- Nahra, Rajaa, et al. "Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study." Diabetes care 44.6 (2021): 1433-1442.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Harrison, Stephen A., et al. "Clinical trial landscape in NASH." Clinical Gastroenterology and Hepatology (2023).‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Prikhodko, Veronika A., Natalia N. Bezborodkina, and Sergey V. Okovityi. "Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates." Biomedicines 10.2 (2022): 274.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Jastreboff, Ania M., et al. "Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial." New England Journal of Medicine 389.6 (2023): 514-526.‏

- Kongmalai, Tanawan, et al. "New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials." Frontiers in Endocrinology 14 (2023): 1182037.‏

- Valenzuela-Vallejo, Laura, Valentina Guatibonza-García, and Christos S. Mantzoros. "Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?." Metabolism 136 (2022): 155248.‏

- dos Santos, Lucas R., et al. "Dipeptidyl peptidase IV inhibitors for nonalcoholic fatty liver disease-systematic review and metanalysis." Current Diabetes Reviews 17.5 (2021): 70-81.‏

- Alam, Shahinul, et al. "Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial." Hepatic medicine: evidence and research (2018): 23-31.‏

- AKTAŞ, Ahmet, and O. Z. A. N. Zeynep. "The efficacy and safety of vildagliptin treatment for nonalcoholic fatty liver disease in type 2 diabetes mellitus." Cumhuriyet Medical Journal 42.4 (2020): 491-499.‏

- Jin, Dachuan, et al. "Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis." Frontiers in Pharmacology 13 (2023): 1096064.‏

- Hattori, Sachiko, et al. "Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis." Diabetology & Metabolic Syndrome 13 (2021): 1-6.‏

- Gupta, Vishal Kumar. "1029-P: Teneligliptin Significantly Reduces Liver Fat Content (LFC) and Delays Progression of NASH in Type 2 Diabetes Mellitus Patients." Diabetes 68.Supplement_1 (2019).‏

- Chen, Lin, et al. "Effect of saxagliptin, a dipeptidyl peptidase 4 inhibitor, on non-alcoholic fatty liver disease." Diabetes, Metabolic Syndrome and Obesity (2020): 3507-3518.‏

- Li, Juan-Juan, et al. "The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data." Revista da Associação Médica Brasileira 65 (2019): 33-37.‏

- Mashitani, Tsuyoshi, et al. "Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes." Biomedical reports 4.2 (2016): 183-187.‏

- Sanyal, Arun J., et al. "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis." New England Journal of Medicine 362.18 (2010): 1675-1685.‏

- Aithal, Guruprasad P., et al. "Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis." Gastroenterology 135.4 (2008): 1176-1184.‏

- Belfort, Renata, et al. "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis." New England Journal of Medicine 355.22 (2006): 2297-2307.‏

- Cusi, Kenneth, et al. "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial." Annals of internal medicine 165.5 (2016): 305-315.‏

- Bril, Fernando, et al. "Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial." Diabetes care 42.8 (2019): 1481-1488.‏

- Della Pepa, Giuseppe, et al. "Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA. IT randomised trial." Diabetes research and clinical practice 178 (2021): 108984.‏

- Ndakotsu, Andrew, and Govinathan Vivekanandan. "The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: A systematic review." Cureus 14.5 (2022).‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Lee, Yong-ho, et al. "Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness." Journal of Korean medical science 32.1 (2017): 60.‏

- Kazierad, David J., et al. "Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial." Med 2.7 (2021): 800-813.‏

- Saxena, Aditi R., et al. "A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes." Diabetes, Obesity and Metabolism 25.4 (2023): 992-1001.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Pinyopornpanish, Kanokwan, et al. "Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels." Gut and liver 15.6 (2021): 827.‏

- Li, Yan, et al. "Metformin in non-alcoholic fatty liver disease: A systematic review and meta analysis." Biomedical reports 1.1 (2013): 57-64.‏

- Musso, G., et al. "Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials." Diabetologia 55 (2012): 885-904.‏

- Loomba, R., et al. "Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis." Alimentary pharmacology & therapeutics 29.2 (2009): 172-182.‏

- Bugianesi, Elisabetta, et al. "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease." Official journal of the American College of Gastroenterology| ACG 100.5 (2005): 1082-1090.‏

- Ioannou, George N. "The role of cholesterol in the pathogenesis of NASH." Trends in Endocrinology & Metabolism 27.2 (2016): 84-95.‏

- Bułdak, Łukasz. "The treatment of heterozygous familial hypercholesterolemia—A local perspective." Endokrynologia Polska 72.3 (2021): 189-190.‏

- Okopień, Bogusław, Łukasz Bułdak, and Aleksandra Bołdys. "Current and future trends in the lipid lowering therapy." Pharmacological Reports 68.4 (2016): 737-747.‏

- Boutari, Chrysoula, et al. "Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis." Clinical Nutrition 41.10 (2022): 2195-2206.‏

- Ahsan, Farah, et al. "Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis." Cureus 12.9 (2020).‏

- Athyros, Vasilios G., et al. "Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study." Current medical research and opinion 22.5 (2006): 873-883.‏

- Athyros, Vasilios G., et al. "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis." The Lancet 376.9756 (2010): 1916-1922.‏

- Cho, Yongin, et al. "Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)." BMC medicine 20.1 (2022): 93.‏

- Lee, Won Myung, et al. "Effect of nutrition education in NAFLD patients undergoing simultaneous hyperlipidemia pharmacotherapy: A randomized controlled trial." Nutrients 13.12 (2021): 4453.‏

- Lee, Hyo Young, et al. "Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis." The Korean journal of internal medicine 34.2 (2019): 296.‏

- Pastori, Daniele, et al. "Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis." British Journal of Clinical Pharmacology 88.2 (2022): 441-451.‏

- Pastori, Daniele, et al. "Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis." British Journal of Clinical Pharmacology 88.2 (2022): 441-451.‏

- Wargny, Matthieu, et al. "Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population." Atherosclerosis 278 (2018): 82-90.‏

- Di Filippo, Mathilde, Benoit Vokaer, and Nabil G. Seidah. "A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease." Journal of clinical lipidology 11.4 (2017): 1101-1105.‏

- Emma, Maria R., et al. "Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis." Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1865.12 (2020): 158792.‏

- Grimaudo, Stefania, et al. "PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD." Liver International 41.2 (2021): 321-332.‏

- Scicali, Roberto, et al. "Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience." Nutrition, Metabolism and Cardiovascular Diseases 31.3 (2021): 869-879.‏

- Shafiq, Muhammad, et al. "Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver." World Journal of Hepatology 12.12 (2020): 1258.‏

- El-Haggar, Sahar Mohamed, and Tarek Mohamed Mostafa. "Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease." Hepatology international 9 (2015): 471-479.‏

- Yaghoubi, Malek, et al. "Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease." European Journal of Gastroenterology & Hepatology 29.12 (2017): 1385-1388.‏

- Oscarsson, Jan, et al. "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study." Journal of clinical lipidology 12.6 (2018): 1390-1403.‏

- Lawitz, Eric J., et al. "Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat." Clinical gastroenterology and hepatology 21.1 (2023): 143-152.‏

- Araki, Eiichi, et al. "Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial." Diabetes Care 41.3 (2018): 538-546.‏

- Ikeda, Suguru, et al. "Pemafibrate dramatically ameliorated the values of liver function tests and fibrosis marker in patients with non-alcoholic fatty liver disease." Yonago acta medica 63.3 (2020): 188-197.‏

- Seko, Yuya, et al. "Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: a single‐arm, pilot study." Hepatology Research 50.12 (2020): 1328-1336.‏

- Shinozaki, Satoshi, et al. "Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease." Clinical and experimental hepatology 6.3 (2020): 270-274.‏

- Hatanaka, Takeshi, et al. "Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: A retrospective, single-arm study." Internal Medicine 60.14 (2021): 2167-2174.‏

- Shinozaki, Satoshi, et al. "Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: A one-year observational study." Clinical and Experimental Hepatology 7.2 (2021): 172-177.‏

- Nakajima, Atsushi, et al. "Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease." Alimentary pharmacology & therapeutics 54.10 (2021): 1263-1277.‏

- Hatanaka, Takeshi, et al. "Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score." JGH Open 5.10 (2021): 1183-1189.

-Morishita, Asahiro, et al. "Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: A multicenter study." Hepatology International 17.3 (2023): 606-614.‏

-Sugimoto, Ryosuke, et al. "Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients." Frontiers in Medicine 10 (2023): 1073025.

- Shinozaki, Satoshi, et al. "Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients." Clinical and Experimental Hepatology 8.4 (2022): 278-283.‏

- Mitra, Asis. "An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease." Cureus 12.7(2020).‏

-Mitra, Asis. "An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease." Cureus 12.7(2020).‏

- Goyal, Omesh, et al. "Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study." Scientific reports 10.1 (2020): 21117.‏

- Rajesh, N. A., et al. "Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia—A Prospective, Interventional, Pilot Study." Journal of Clinical and Experimental Hepatology 12.1 (2022): 61-67.‏

- Padole, Prateek, et al. "Saroglitazar for nonalcoholic fattyliver disease: a single centre experience in 91 patients." Journal of Clinical and Experimental Hepatology 12.2 (2022): 435-439.‏

- Siddiqui, Mohammad Shadab, et al. "Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis." Clinical Gastroenterology and Hepatology 21.10 (2023): 2597-2605.‏

- Malik, Adnan, Mahum Nadeem, and Muhammad Imran Malik. "Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: A systematic review and meta-analysis." Clinical Journal of Gastroenterology 14.6 (2021): 1579-1586.‏

- Kotsiliti, Eleni. "Lanifibranor and NASH resolution." Nature reviews Gastroenterology & hepatology 18.12 (2021): 832-832.‏

-Fabbrini, Elisa, Shelby Sullivan, and Samuel Klein. "Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications." Hepatology 51.2 (2010): 679-689.‏

- Lambert, Jennifer E., et al. "Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease." Gastroenterology 146.3 (2014): 726-735.‏

- Kim, Chai-Wan, et al. "Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation." Cell metabolism 26.2 (2017): 394-406.‏

- Loomba, Rohit, et al. "GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease." Gastroenterology 155.5 (2018): 1463-1473.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- O’Farrell, Marie, et al. "FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models." Scientific Reports 12.1 (2022): 15661.‏

- Syed‐Abdul, Majid M., et al. "Fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities." Hepatology 72.1 (2020): 103-118.‏

- Loomba, Rohit, et al. "TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial." Gastroenterology 161.5 (2021): 1475-1486.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Calle, Roberto A., et al. "ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials." Nature Medicine 27.10 (2021): 1836-1848.‏

- Amin, Neeta B., et al. "Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study." BMJ open 12.3 (2022): e056159.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Woo, Y. C., et al. "Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives." Clinical endocrinology 78.4 (2013): 489-496.‏

- Loomba, Rohit, et al. "Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study." The Lancet Gastroenterology & Hepatology 8.2 (2023): 120-132.‏

- Loomba, Rohit, et al. "Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH." New England Journal of Medicine 389.11 (2023): 998-1008.‏

- To Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (ENTRUST). Available online: https://classic.clinicaltrials.gov/ct2/show/NCT05852431 (accessed on 24 September 2023).

- Puengel, Tobias, and Frank Tacke. "Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)." Expert Opinion on Investigational Drugs 32.6 (2023): 451-461.‏ [185]- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Zhang, Wenyue, et al. "Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials." Asia Pacific Journal of Clinical Nutrition 29.4 (2020): 696-705.‏

- Lin, Xiaozhuan, et al. "Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis." Expert Review of Gastroenterology & Hepatology 16.6 (2022): 537-545.‏

- Ferro, Domenico, et al. "New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress." Nutrients 12.9 (2020): 2762.‏

- An, Lingxuan, et al. "The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases." Journal of Gastrointestinal Surgery 26.3 (2022): 671-683.‏

- Carpi, Rodrigo Zamignan, et al. "The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A systematic review." International journal of molecular sciences 23.15 (2022): 8805.‏

- Sharpton, Suzanne R., et al. "Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression." The American journal of clinical nutrition 110.1 (2019): 139-149.‏

- Davani-Davari, Dorna, et al. "Prebiotics: definition, types, sources, mechanisms, and clinical applications." Foods 8.3 (2019): 92.‏

- Huang, Yuanshe, et al. "Effect of probiotics therapy on nonalcoholic fatty liver disease." Computational and mathematical methods in medicine 2022.1 (2022): 7888076.‏

- Mavilia-Scranton, Marianna G., George Y. Wu, and Murali Dharan. "Impact of Helicobacter pylori infection on the pathogenesis and management of nonalcoholic fatty liver disease." Journal of Clinical and Translational Hepatology 11.3 (2023): 670.‏

- Xu, Guangqin, et al. "Relationship of Helicobacter pylori infection with nonalcoholic fatty liver disease: a meta‐analysis." Canadian Journal of Gastroenterology and Hepatology 2023.1 (2023): 5521239.‏

- Malfertheiner, Peter, et al. "Helicobacter pylori infection." Nature reviews Disease primers 9.1 (2023): 19.‏

- Aydemir, Selim, et al. "The effect of Helicobacter pylori on insulin resistance." Digestive diseases and sciences 50 (2005): 2090-2093.‏

- Chen, Li-Wei, et al. "Helicobacter pylori infection increases insulin resistance and metabolic syndrome in residents younger than 50 years old: a community-based study." PloS one 10.5 (2015): e0128671.‏

- Chen, Chen, et al. "Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome." European journal of gastroenterology & hepatology 32.7 (2020): 857-866.‏

- Azami, Mobin, et al. "Association of Helicobacter pylori infection with the risk of metabolic syndrome and insulin resistance: an updated systematic review and meta-analysis." Diabetology & metabolic syndrome 13.1 (2021): 145.‏

- Tsuji, Ai, et al. "Tactics with prebiotics for the treatment of metabolic dysfunction-associated fatty liver disease via the improvement of mitophagy." International Journal of Molecular Sciences 24.6 (2023): 5465.‏

- Arellano-García, Laura, et al. "Usefulness of probiotics in the management of NAFLD: evidence and involved mechanisms of action from preclinical and human models." International Journal of Molecular Sciences 23.6 (2022): 3167.‏

- Dong, Yuzhu, et al. "Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure." BMC Infectious Diseases 22.1 (2022): 23.‏

- Gangarapu, Venkatanarayana, et al. "Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease." European journal of gastroenterology & hepatology 27.7 (2015): 840-845.‏

- Abdel-Razik, Ahmed, et al. "Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot." European journal of gastroenterology & hepatology 30.10 (2018): 1237-1246.‏

- Ponziani, Francesca Romana, et al. "Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation." World journal of gastroenterology 23.25 (2017): 4491.‏

- Chen, Hui-Ting, et al. "Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view." World journal of gastroenterology 26.16 (2020): 1901.‏

- Chen, Hui-Ting, et al. "Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view." World journal of gastroenterology 26.16 (2020): 1901.‏

- Podszun, Maren C., and Jan Frank. "Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease." Redox Biology 42 (2021): 101937.‏

- Luo, Qian, et al. "Efficacy of off-label therapy for non-alcoholic fatty liver disease in improving non-invasive and invasive biomarkers: a systematic review and network meta-analysis of randomized controlled trials." Frontiers in Medicine 9 (2022): 793203.‏

- An, Jihyun, and Joo Hyun Sohn. "Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials." Clinical and Molecular Hepatology 29.Suppl (2023): S268.‏

- Lahmi, A., et al. "Comparative effects of thymol and vitamin E on nonalcoholic fatty liver disease in male Wistar rats." Brazilian Journal of Biology 84 (2023): e268781.‏

- Bai, Yaowei, et al. "Aerobic exercise and vitamin E improve high-fat diet-induced NAFLD in rats by regulating the AMPK pathway and oxidative stress." European Journal of Nutrition 62.6 (2023): 2621-2632.‏

- Vadarlis, Andreas, et al. "Systematic review with meta‐analysis: the effect of vitamin E supplementation in adult patients with non‐alcoholic fatty liver disease." Journal of Gastroenterology and Hepatology 36.2 (2021): 311-319.‏

- Abdel-Maboud, Mohamed, et al. "The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression." Therapeutic advances in gastroenterology 13 (2020): 1756284820974917.‏

- Bułdak, Łukasz, et al. "Endocrine diseases as causes of secondary hyperlipidemia." Endokrynologia Polska 70.6 (2019): 511-519.‏

- Tanase, Daniela Maria, et al. "Hypothyroidism-induced nonalcoholic fatty liver disease (HIN): mechanisms and emerging therapeutic options." International Journal of Molecular Sciences 21.16 (2020): 5927.‏

- Harrison, Stephen A., et al. "Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial." The Lancet 394.10213 (2019): 2012-2024.‏

- Harrison, Stephen A., et al. "Effects of resmetirom on noninvasive endpoints in a 36‐week phase 2 active treatment extension study in patients with NASH." Hepatology communications 5.4 (2021): 573-588.‏

- Phase, A. "Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)." ClinicalTrials. gov ClinicalTrials. gov https://clinicaltrials. gov/ct2/show/NCT04951219 Identifier: NCT04951219. Available at:(accessed 14 September 2022) (3).‏

- Polyzos, Stergios A., et al. "Nonalcoholic fatty liver disease in males with low testosterone concentrations." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14.5 (2020): 1571-1577.‏

- Yassin, Aksam A., et al. "Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study." The Aging Male 23.5 (2020): 1553-1563.‏

- Patil, Vaibhav, et al. "Versatility of anabolic androgenic steroid–induced hepatotoxicity." Journal of Clinical and Experimental Hepatology 12.1 (2022): 216-221.‏

- Palmisano, Brian T., Lin Zhu, and John M. Stafford. "Role of estrogens in the regulation of liver lipid metabolism." Sex and gender factors affecting metabolic homeostasis, diabetes and obesity (2017): 227-256.‏

- Gutierrez-Grobe, Ylse, et al. "Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens." Annals of hepatology 9.4 (2010): 402-409.‏

- Cao, Weijie, et al. "Associations between sex hormones and metabolic-associated fatty liver disease in a middle-aged and elderly community." Endocrine Journal 69.8 (2022): 1007-1014.‏

- Polyzos, Stergios A., Irene Lambrinoudaki, and Dimitrios G. Goulis. "Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease." Hormones 21.3 (2022): 375-381.‏

- DiStefano, Johanna K. "NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment." Endocrinology 161.10 (2020): bqaa134.‏

- Florio, Andrea A., et al. "Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the Clinical Practice Research Datalink." European journal of epidemiology 34 (2019): 871-878.‏

- Oxley, Madisyn, Heather Francis, and Keisaku Sato. "Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies." Seminars in Liver Disease. Vol. 43. No. 01. Thieme Medical Publishers, Inc., 2023.‏

- Hwang, Yoon-A., et al. "Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma." Frontiers in Endocrinology 13 (2023): 1057769.‏

-Dichtel, Laura E., et al. "The GH/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity." The Journal of Clinical Endocrinology & Metabolism 107.9 (2022): e3624-e3632.‏

- Pan, Chelsea S., et al. "Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease." Clinical endocrinology 94.2 (2021): 183-192.‏

- Liu, Zhengtao, et al. "Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies." Scientific Reports 5.1 (2015): 14325.‏

- Nishikawa, Tomoki, et al. "Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice." Scientific reports 10.1 (2020): 815.‏

- Kakimoto, Mai, et al. "Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats." Journal of Applied Biomedicine 21.2 (2023).‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- Kessoku, Takaomi, et al. "The role of leaky gut in nonalcoholic fatty liver disease: a novel therapeutic target." International Journal of Molecular Sciences 22.15 (2021): 8161.‏

-Wilson, Nicholas, and Ron Schey. "Lubiprostone in constipation: clinical evidence and place in therapy." Therapeutic advances in chronic disease 6.2 (2015): 40-50.‏

- Kim, Mi-Yeon, et al. "Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice." Life Sciences 311 (2022): 121176.‏

- Kessoku, Takaomi, et al. "Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial." The lancet Gastroenterology & hepatology 5.11 (2020): 996-1007.‏

- Bołdys, Aleksandra, et al. "Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease." Medicina 59.10 (2023): 1789.‏

- El‐Deen, Reham M., et al. "Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high‐fat diet‐induced nonalcoholic fatty liver in rats." Fundamental & Clinical Pharmacology 34.3 (2020): 353-364.‏

- Vachliotis, Ilias D., and Stergios A. Polyzos. "The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease." Current obesity reports 12.3 (2023): 191-206.‏

- Du, Juan, et al. "Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis." World journal of gastroenterology: WJG 20.2 (2014): 569.‏

- Ipsen, David Højland, et al. "The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non‐alcoholic steatohepatitis." Basic & Clinical Pharmacology & Toxicology 128.4 (2021): 583-593.‏

- Mahjoubin-Tehran, Maryam, et al. "Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis." Molecular Metabolism 50 (2021): 101049.‏

- Malladi, Navya, et al. "The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics." Prostaglandins & Other Lipid Mediators 169 (2023): 106766.‏

- Meng, Chang, et al. "Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial." Open Life Sciences 18.1 (2023): 20220583.‏

- Surma, Stanisław, et al. "Curcumin-the nutraceutical with pleiotropic effects? Which cardiometabolic subjects might benefit the most?." Frontiers in Nutrition 9 (2022): 865497.‏

- Cicero, Arrigo FG, et al. "Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel." Nutrition reviews 75.9 (2017): 731-767.‏

- Banach, Maciej, et al. "PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021." Archives of Medical Science: AMS 17.6 (2021): 1447.‏

- Ruscica, Massimiliano, et al. "Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases–A position paper from the International Lipid Expert Panel (ILEP)." Progress in cardiovascular diseases 67 (2021): 40-52.‏

- Ashtary-Larky, Damoon, et al. "The effects of nano-curcumin supplementation on risk factors for cardiovascular disease: a GRADE-assessed systematic review and meta-analysis of clinical trials." Antioxidants 10.7 (2021): 1015.‏

- Ngu, M. H., et al. "Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: A systematic review and meta-analysis." Complementary Therapies in Medicine 68 (2022): 102843.‏

- Lukkunaprasit, Thitiya, et al. "An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand." Scientific Reports 13.1 (2023): 5824.‏

- Surma, Stanisław, and Franciszek Kokot. "Influence of chronic coffee consumption on the risk of kidney and other organ diseases. Review of the literature and clinical studies." Renal Disease and Transplantation Forum. Vol. 15. No. 1. 2022.‏

- Surma, Stanisław, Amirhossein Sahebkar, and Maciej Banach. "Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention." Pharmacological Research 187 (2023): 106596.‏

- Ding, Ming, et al. "Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis." Diabetes care 37.2 (2014): 569-586.‏

- Ding, Ming, et al. "Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis." Diabetes care 37.2 (2014): 569-586.‏

- Surma, Stanisław, and Maciej Banach. "Coffee and caffeine consumption and overall mortality. Pleasure with restrictions-where do we really stand in 2022?." Nutrition (Burbank, Los Angeles County, Calif.) 102 (2022): 111747.‏

- Sewter, Rebecca, Susan Heaney, and Amanda Patterson. "Coffee consumption and the progression of NAFLD: a systematic review." Nutrients 13.7 (2021): 2381.‏

- Hayat, Umar, et al. "The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies." Annals of hepatology 20 (2021): 100254.‏

- Kositamongkol, Chayanis, et al. "Coffee consumption and non-alcoholic fatty liver disease: an umbrella review and a systematic review and meta-analysis." Frontiers in pharmacology 12 (2021): 786596.‏

- Kennedy, O. J., et al. "Systematic review with meta‐analysis: coffee consumption and the risk of cirrhosis." Alimentary pharmacology & therapeutics 43.5 (2016): 562-574.‏

- Poole, Robin, et al. "Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes." bmj 359 (2017).‏

- Salehi, Bahare, et al. "Resveratrol: A double-edged sword in health benefits." Biomedicines 6.3 (2018): 91.‏

- Zhang, Chongyang, et al. "Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: a meta-analysis of placebo-controlled clinical trials." PLoS One 11.8 (2016): e0161792.‏

- Jakubczyk, Karolina, et al. "Effects of resveratrol supplementation in patients with non-alcoholic fatty liver disease—A meta-analysis." Nutrients 12.8 (2020): 2435.‏

- Adamczak, Marcin, Stanisław Surma, and Andrzej Więcek. "Vitamin D and arterial hypertension: facts and myths." Current Hypertension Reports 22 (2020): 1-8.‏

- de la Guía-Galipienso, Fernando, et al. "Vitamin D and cardiovascular health." Clinical Nutrition 40.5 (2021): 2946-2957.‏

- Eliades, M., et al. "Meta‐analysis: vitamin D and non‐alcoholic fatty liver disease." Alimentary pharmacology & therapeutics 38.3 (2013): 246-254.‏

- Sindhughosa, Dwijo Anargha, et al. "Additional treatment of vitamin D for improvement of insulin resistance in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis." Scientific Reports 12.1 (2022): 7716.‏

- Rezaei, Shahla, Maryam Gholamalizadeh, and Saeid Doaei. "The effects of vitamin D supplementation on anthropometric and biochemical indices in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis." Frontiers in Pharmacology 12 (2021): 732496.‏

- Rizzo, Manfredi, et al. "Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)." Pharmacological research 189 (2023): 106679.‏

- Yan, Jian-Hui, et al. "Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials." Medicine 97.37 (2018): e12271.‏

- Moore, Ella, et al. "A systematic review and meta-analysis of randomized controlled trials to evaluate plant-based omega-3 polyunsaturated fatty acids in nonalcoholic fatty liver disease patient biomarkers and parameters." Nutrition Reviews (2023): nuad054.‏

- Federico, Alessandro, Marcello Dallio, and Carmelina Loguercio. "Silymarin/silybin and chronic liver disease: a marriage of many years." Molecules 22.2 (2017): 191.‏

- Kalopitas, Georgios, et al. "Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis." Nutrition 83 (2021): 111092.‏

- Surma, Stanisław, et al. "Garlic for arterial hypertension and hypercholesterolaemia. Review of literature studies and clinical studies." Folia Cardiologica 16.5 (2021): 296-302.‏

- Yu, Leilei, et al. "Effects of garlic supplementation on non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials." Journal of Functional Foods 99 (2022): 105294.‏

- Rastkar, Mohsen, et al. "Systematic review and meta-analysis of the effect of garlic in patients with non-alcoholic fatty liver disease." Indian Journal of Gastroenterology 41.6 (2022): 548-557.‏

- Wiering, Leke, and Frank Tacke. "Treating inflammation to combat non-alcoholic fatty liver disease." Journal of Endocrinology 256.1 (2023).‏




DOI: http://dx.doi.org/10.52155/ijpsat.v45.1.6350

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Maged Naser

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.